PTCT Q3 2019 Earnings — PTC Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

PTCTPTC Therapeutics, Inc.

$5B

Q3 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$71M+33.3% YoY

Gross Profit

$68M95.8% margin

Operating Income

-$60M-84.7% margin

Net Income

-$60M-84.0% margin

EPS (Diluted)

$-1.06

QoQ Revenue Growth

-16.5%

Cash Flow

Operating Cash Flow

-$16M

Free Cash Flow

-$28M

Stock-Based Comp.

$10M

Balance Sheet

Total Assets

$1.6B

Total Liabilities

$978M

Stockholders' Equity

$664M

Cash & Equivalents

$524M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$71M	$54M	+33.3%
Gross Profit	$68M	$50M	+36.0%
Operating Income	-$60M	-$48M	-25.4%
Net Income	-$60M	-$51M	-17.7%

Revenue Segments

Product

$71M100%

Grant And Collaboration

$47,0000%